📊 VTAK Key Takeaways
Is Catheter Precision, Inc. (VTAK) a Good Investment?
Catheter Precision exhibits excellent gross margins (90.3%) and strong revenue growth (95% YoY), indicating product traction, but faces critical financial distress with a liquidity crisis (0.06x current ratio), only $441K cash against $2.8M annual burn, and unsustainable operating losses (-536% margin). The company has approximately 1-2 months of cash runway and presents severe going concern risk absent immediate capital infusion.
Why Buy Catheter Precision, Inc. Stock? VTAK Key Strengths
- Exceptional gross margin (90.3%) indicates strong product economics and market acceptance
- Robust revenue growth (95% YoY) demonstrates market traction from commercialization
- Improving operational performance (EPS improved 89.5% YoY shows trend optimization)
- Conservative leverage (0.32x Debt/Equity) avoids overleveraging during growth phase
- High-barrier medical device sector with regulatory moats
VTAK Stock Risks: Catheter Precision, Inc. Investment Risks
- Critical liquidity crisis - current ratio of 0.06x indicates severe inability to service short-term obligations
- Severe cash burn ($2.8M annually) with minimal runway - only ~1.5 months of cash remaining
- Massive operating losses (-$2.3M on $432K revenue; -536% operating margin)
- Microscopic revenue base indicates very early commercialization stage with unproven scalability
- Going concern risk requiring immediate dilutive capital raise, debt restructuring, or strategic intervention
- Negative cash flow from operations despite revenue generation indicates unit economics challenges
Key Metrics to Watch
- Cash position and timeline to next funding round or profitability
- Operating cash flow trajectory and path to positive OCF
- Revenue growth sustainability at current 95% YoY rate
- Working capital efficiency and current ratio improvement from 0.06x
- Capital raise announcements, terms, and dilution impact
Catheter Precision, Inc. (VTAK) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
VTAK Profit Margin, ROE & Profitability Analysis
VTAK vs Healthcare Sector: How Catheter Precision, Inc. Compares
How Catheter Precision, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Catheter Precision, Inc. Stock Overvalued? VTAK Valuation Analysis 2026
Based on fundamental analysis, Catheter Precision, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Catheter Precision, Inc. Balance Sheet: VTAK Debt, Cash & Liquidity
VTAK Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Catheter Precision, Inc.'s revenue has declined by 89% over the 5-year period, indicating business contraction. The most recent EPS of $-248.22 indicates the company is currently unprofitable.
VTAK Revenue Growth, EPS Growth & YoY Performance
VTAK Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $143.0K | -$1.7M | $-1.39 |
| Q3 2025 | $96.0K | -$2.3M | $-1.70 |
| Q2 2025 | $93.0K | -$4.2M | $-0.38 |
| Q1 2025 | $82.0K | -$2.7M | $-0.36 |
| Q1 2023 | $9.0K | -$5.5M | N/A |
| Q3 2022 | $5.0K | -$4.3M | $-4.36 |
| Q2 2022 | $5.0K | -$5.2M | $-0.26 |
| Q1 2022 | $4.0K | -$5.5M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Catheter Precision, Inc. Dividends, Buybacks & Capital Allocation
VTAK SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Catheter Precision, Inc. (CIK: 0001716621)
📋 Recent SEC Filings
❓ Frequently Asked Questions about VTAK
What is the AI rating for VTAK?
Catheter Precision, Inc. (VTAK) has an AI rating of STRONG SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are VTAK's key strengths?
Claude: Exceptional gross margin (90.3%) indicates strong product economics and market acceptance. Robust revenue growth (95% YoY) demonstrates market traction from commercialization.
What are the risks of investing in VTAK?
Claude: Critical liquidity crisis - current ratio of 0.06x indicates severe inability to service short-term obligations. Severe cash burn ($2.8M annually) with minimal runway - only ~1.5 months of cash remaining.
What is VTAK's revenue and growth?
Catheter Precision, Inc. reported revenue of $432.0K.
Does VTAK pay dividends?
Catheter Precision, Inc. does not currently pay dividends.
Where can I find VTAK SEC filings?
Official SEC filings for Catheter Precision, Inc. (CIK: 0001716621) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is VTAK's EPS?
Catheter Precision, Inc. has a diluted EPS of $-25.98.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is VTAK a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Catheter Precision, Inc. has a STRONG SELL rating with 85% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is VTAK stock overvalued or undervalued?
Valuation metrics for VTAK: ROE of -17.6% (sector avg: 15%), net margin of -389.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy VTAK stock in 2026?
Our dual AI analysis gives Catheter Precision, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is VTAK's free cash flow?
Catheter Precision, Inc.'s operating cash flow is $-2.8M, with capital expenditures of $6.0K. FCF margin is -648.6%.
How does VTAK compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -389.1% (avg: 12%), ROE -17.6% (avg: 15%), current ratio 0.06 (avg: 2).